Aliases & Classifications for Urticaria

Aliases & Descriptions for Urticaria:

Name: Urticaria 12 29 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1555
ICD9CM 35 708.8
ICD10 33 L50
UMLS 69 C0029839

Summaries for Urticaria

Disease Ontology : 12 A skin disease characterized by skin rash notable for pale red, raised and itchy bumps, located in the upper dermis.

MalaCards based summary : Urticaria is related to angioedema and vibratory urticaria, and has symptoms including abdominal pain, chest pain and constipation. An important gene associated with Urticaria is NLRP3 (NLR Family Pyrin Domain Containing 3), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and Development VEGF signaling via VEGFR2 - generic cascades. The drugs Clarinex and Histamine have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and thyroid, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and cardiovascular system

Related Diseases for Urticaria

Diseases related to Urticaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 250)
id Related Disease Score Top Affiliating Genes
1 angioedema 28.5 ADGRE2 AOC1 C1S CMA1 FCER1A FCER2
2 vibratory urticaria 12.4
3 cold urticaria 12.3
4 cholinergic urticaria 12.3
5 aquagenic urticaria 12.3
6 solar urticaria 12.3
7 urticaria pigmentosa 12.2
8 physical urticaria 12.2
9 allergic urticaria 12.0
10 papular urticaria 11.9
11 schnitzler syndrome 11.9
12 nodular urticaria pigmentosa 11.8
13 muckle-wells syndrome 11.8
14 plaque-form urticaria pigmentosa 11.7
15 typical urticaria pigmentosa 11.7
16 familial cold autoinflammatory syndrome 3 11.7
17 dermatographia 11.6
18 familial cold-induced inflammatory syndrome 1 11.4
19 maculopapular cutaneous mastocytosis 11.4
20 mast cell disease 11.2
21 exercise-induced anaphylaxis 11.0
22 cutaneous mastocytosis 11.0
23 cryopyrin-associated periodic syndrome 11.0
24 peanut allergy 11.0
25 wheat allergy 11.0
26 familial cold autoinflammatory syndrome 11.0
27 familial dermographism 10.8
28 arthus reaction 10.7
29 carboxypeptidase n deficiency 10.7
30 anca-associated vasculitis 10.7
31 paragonimiasis 10.7
32 monoclonal mast cell activation syndrome 10.7
33 episodic angioedema with eosinophilia 10.7
34 hypersensitivity vasculitis 10.7
35 fascioliasis 10.7
36 hypocomplementemic urticarial vasculitis 10.7
37 cystic echinococcosis 10.7
38 diffuse intraductal papillomatosis 10.2 FCER1A MS4A2
39 mastocytosis 10.2
40 intravascular angioleiomyoma 10.2 MS4A2 NLRP3 RNASE3
41 erythema multiforme 10.2
42 3mc syndrome 10.2 ADGRE2 FCER1A MS4A2
43 marasmus 10.2 LTC4S RNASE3
44 coloboma of optic papilla 10.2 CMA1 NLRP3 PLCG2 RNASE3
45 dermatitis 10.1
46 thyroiditis 10.1
47 apricot allergy 10.1 AOC1 CMA1 RNASE3
48 pagon stephan syndrome 10.1 PTGS1 PTGS2
49 acro coxo mesomelic dysplasia 10.1 C1S SERPING1
50 hypersensitivity syndrome, carbamazepine-induced 10.1

Comorbidity relations with Urticaria via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential
Ischemic Heart Disease

Graphical network of the top 20 diseases related to Urticaria:



Diseases related to Urticaria

Symptoms & Phenotypes for Urticaria

UMLS symptoms related to Urticaria:


abdominal pain, chest pain, constipation, coughing, diarrhea, dyspepsia, edema, exanthema, fatigue, fever, halitosis, headache, heartburn, icterus, nausea and vomiting, pain, pelvic pain, pruritus, sciatica, syncope, chronic pain, welts, vertigo/dizziness, gastrointestinal gas, symptoms

GenomeRNAi Phenotypes related to Urticaria according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.5 PTGS2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.5 HNMT
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.5 PTGS2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.5 PTGS2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.5 HNMT
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.5 PTGS2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.5 SERPING1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.5 PTGS2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.5 HRH2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.5 PTGS2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.5 HNMT
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.5 HNMT HRH2 PTGS2 SERPING1

MGI Mouse Phenotypes related to Urticaria:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.81 AOC1 FCER1A LTC4S PLCG2 PTGS1 PTGS2
2 hematopoietic system MP:0005397 9.7 AOC1 CMA1 FCER1A FCER2 HRH1 MS4A2
3 immune system MP:0005387 9.36 NLRP3 PLCG2 PTGS1 PTGS2 SELE CMA1

Drugs & Therapeutics for Urticaria

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Clarinex 17 DESLORATADINE Schering-Plough Approved February 2002

Drugs for Urticaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 280)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
2
Levocetirizine Approved Phase 4,Phase 3,Phase 2 130018-77-8
3
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1 83881-51-0 2678
4
Desloratadine Approved, Investigational Phase 4,Phase 3,Phase 2 100643-71-8 124087
5
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 242138-07-4
6
Fexofenadine Approved Phase 4,Phase 2 83799-24-0 3348
7
Icatibant Approved Phase 4,Phase 3,Phase 2,Phase 1 138614-30-9, 130308-48-4 71364
8
Azelastine Approved Phase 4,Phase 3 58581-89-8 2267
9
Loratadine Approved Phase 4,Phase 3,Phase 2 79794-75-5 3957
10
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
11
Cefazolin Approved Phase 4 25953-19-9 656510 33255
12
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
13
Hydroxyzine Approved Phase 4 68-88-2 3658
14
Clevidipine Approved Phase 4 167221-71-8
15
Dapsone Approved, Investigational Phase 4 80-08-0 2955
16
Menthol Approved Phase 4 2216-51-5 16666
17
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 54575, 6560146 143
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
19
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
20
Bradykinin Phase 4,Phase 3,Phase 2,Phase 1 58-82-2 439201
21
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-74-1 65513
22
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 Cholinergic Agents Phase 4,Phase 3,Phase 2
24 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
25 Cholinergic Antagonists Phase 4,Phase 3,Phase 2
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1
30 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 3,Phase 2
31 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Vaccines Phase 4,Phase 2
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
36 Vitamin B Complex Phase 4,Phase 3,Phase 2
37 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Immunoglobulin E Phase 4
40 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Kininogens Phase 4,Phase 3,Phase 2,Phase 1
44 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
46 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Antipruritics Phase 4,Phase 3,Phase 2
50 vitamin d Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 308)
id Name Status NCT ID Phase
1 The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria Unknown status NCT00346606 Phase 4
2 Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses Completed NCT01250652 Phase 4
3 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed NCT02550106 Phase 4
4 Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Completed NCT01444196 Phase 4
5 Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria Completed NCT01940393 Phase 4
6 A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions Completed NCT00600847 Phase 4
7 CUTE (Chronic Urticaria Treatment Evaluation) Completed NCT00264303 Phase 4
8 Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) Completed NCT00536380 Phase 4
9 A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) Completed NCT00783354 Phase 4
10 An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540) Completed NCT00795522 Phase 4
11 A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) Completed NCT00751218 Phase 4
12 Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Completed NCT02576041 Phase 4
13 A Post Marking Study to Evaluate the Safety of FluMist in Children Completed NCT00569894 Phase 4
14 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4
15 Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Completed NCT01121458 Phase 4
16 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
17 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4
18 Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR Completed NCT01880840 Phase 4
19 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
20 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
21 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4
22 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
23 Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation Recruiting NCT02742805 Phase 4
24 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Recruiting NCT02550080 Phase 4
25 Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria Active, not recruiting NCT01701583 Phase 4
26 A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU) Active, not recruiting NCT02392624 Phase 4
27 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Not yet recruiting NCT03111628 Phase 4
28 Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody Not yet recruiting NCT03183024 Phase 4
29 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4
30 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Not yet recruiting NCT02966314 Phase 4
31 A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736) Terminated NCT00751166 Phase 4
32 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated NCT01574248 Phase 4
33 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4
34 Methotrexate in the Treatment of Chronic Idiopathic Urticaria Unknown status NCT01960283 Phase 3
35 Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria Unknown status NCT02166151 Phase 3
36 Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria Unknown status NCT02372604 Phase 3
37 Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) Completed NCT00598611 Phase 3
38 Bilastine Updosing in Chronic Spontaneous Urticaria Completed NCT02213367 Phase 3
39 Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency Completed NCT02565680 Phase 2, Phase 3
40 Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria Completed NCT01715740 Phase 3
41 Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria Completed NCT00421109 Phase 3
42 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients Completed NCT02161562 Phase 3
43 An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) Completed NCT01916967 Phase 3
44 How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988) Completed NCT00795158 Phase 3
45 Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Completed NCT01803763 Phase 2, Phase 3
46 Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria Completed NCT00525382 Phase 3
47 A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Completed NCT01264939 Phase 3
48 Bilastine Updosing - Characterization of Underlying Mechanisms Completed NCT01271075 Phase 2, Phase 3
49 Multicenter Pilot Phase III Clinical Trials of JDP-205 iv Injection for the Treatment of Acute Urticaria Associated With an Acute Allergic Reaction. Completed NCT02023164 Phase 3
50 Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin Completed NCT00619801 Phase 3

Search NIH Clinical Center for Urticaria

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Urticaria

Genetic tests related to Urticaria:

id Genetic test Affiliating Genes
1 Urticaria 29

Anatomical Context for Urticaria

MalaCards organs/tissues related to Urticaria:

39
Skin, Testes, Thyroid, Bone, T Cells, Neutrophil, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Urticaria:

18
The Upper Dermis

Publications for Urticaria

Articles related to Urticaria:

(show top 50) (show all 1667)
id Title Authors Year
1
Atopic Dermatitis and Allergic Urticaria: Cutaneous Manifestations of Immunodeficiency. ( 27886899 )
2017
2
Clinical characteristics in cholinergic urticaria with palpebral angioedema: Report of 15 cases. ( 27876252 )
2017
3
Synergistic Actions of Histamine-Releasing Factor and Histamine Releasing Factor-Reactive IgE in Chronic Urticaria. ( 28219065 )
2017
4
Looking forward to new targeted treatments for chronic spontaneous urticaria. ( 28078079 )
2017
5
Seroprevalence of Toxocariasis In Children With Urticaria: A Population-Based Study. ( 28077610 )
2017
6
Investigation of thiol-disulphide balance in patients with acute urticaria and chronic spontaneous urticaria. ( 27927024 )
2017
7
Visible light-induced solar urticaria is improved by omalizumab. ( 27622987 )
2016
8
Copy number variation in ALOX5 and PTGER1 is associated with NSAIDs-induced urticaria and/or angioedema. ( 26959713 )
2016
9
Coexistence of granuloma annulare and chronic spontaneous urticaria. ( 27579763 )
2016
10
Omalizumab for chronic urticaria in Latin America. ( 27942350 )
2016
11
Cold urticaria: a 20-year follow-up study. ( 27422852 )
2016
12
Co-Occurrence of Chronic Spontaneous Urticaria with Immunoglobulin A Deficiency and Autoimmune Diseases. ( 27073906 )
2016
13
Autoimmune progesterone dermatitis: Case report with history of urticaria, petechiae and palpable pinpoint purpura triggered by medical abortion. ( 27032848 )
2016
14
A case of aquagenic urticaria successfully treated with omalizumab. ( 26852068 )
2016
15
Infrared radiation increases skin damage induced by other wavelengths in solar urticaria. ( 27622861 )
2016
16
Effectiveness of omalizumab in severe solar urticaria. ( 26803538 )
2016
17
Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. ( 27911016 )
2016
18
Rare cause of recurrent urticaria in childhood and its unusual presentation: Solitary mastocytoma on vulva. ( 27206703 )
2016
19
Somatic STAT5b gain of function mutations in early-onset non-clonal eosinophilia, urticaria, dermatitis and diarrhea. ( 27956386 )
2016
20
Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study. ( 27599913 )
2016
21
Serum Clusterin as a Prognostic Marker of Chronic Spontaneous Urticaria. ( 27175709 )
2016
22
A prospective ten-year follow-up of patients with chronic urticaria. ( 27083494 )
2016
23
Elevation of serum carcinoembryonic antigen in a case of cholinergic urticaria with failed detection of hypohidrosis by the conventional starch-iodine test. ( 27864842 )
2016
24
Home Self-Administration of Omalizumab for Chronic Spontaneous Urticaria. ( 27639259 )
2016
25
General Anesthesia in a Patient With Urticaria Pigmentosa Referred for Electroconvulsive Therapy. ( 26934274 )
2016
26
The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review. ( 27185439 )
2016
27
Aquagenic Urticaria: Report of a Case in an Adolescent Girl. ( 27763863 )
2016
28
Oxidative Stress in Children with Chronic Spontaneous Urticaria. ( 27127547 )
2016
29
Vibratory Urticaria Associated with a Missense Variant in ADGRE2. ( 26841242 )
2016
30
Direct Medical Costs of Chronic Urticaria in a Private Health Organization of Buenos Aires, Argentina. ( 27986199 )
2016
31
Chronic spontaneous urticaria associated with primary biliary cirrhosis: a case report and literature review. ( 27879079 )
2016
32
Diagnostic utility of challenge procedures for physical urticaria/angioedema syndromes: a systematic review. ( 27585061 )
2016
33
New Etiology of Cholinergic Urticaria. ( 27584968 )
2016
34
Second-Generation H1-Antihistamines for Chronic Spontaneous Urticaria. ( 27583420 )
2016
35
Exercise-induced urticaria, cholinergic urticaria, and Kounis syndrome. ( 27127399 )
2016
36
Upregulated expression of substance P in basophils of the patients with chronic spontaneous urticaria: induction of histamine release and basophil accumulation by substance P. ( 27147256 )
2016
37
Addition of lafutidine can improve disease activity and lead to better quality of life in refractory cholinergic urticaria unresponsive to histamine H1 antagonists. ( 26896422 )
2016
38
Omalizumab in patients with severe and refractory solar urticaria: A phase II multicentric study. ( 26892659 )
2016
39
Comparative efficacy of bilastine, levocetirizine and desloratadine updosing in chronic urticaria. ( 27932886 )
2016
40
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria. ( 27209583 )
2016
41
Is There an Association between Restless Legs Syndrome and Urticaria? ( 27134503 )
2016
42
Solar urticaria: Epidemiology and clinical phenotypes in a Spanish series of 224 patients. ( 27793344 )
2016
43
Unexpected cause of urticaria. ( 27078599 )
2016
44
Cosmetic components causing contact urticaria: a review and update. ( 27593503 )
2016
45
Atopic predisposition in cholinergic urticaria patients and its implications. ( 27324252 )
2016
46
Rapid response to omalizumab in 3 cases of delayed pressure urticaria. ( 27665388 )
2016
47
Circulating soluble receptor for advanced glycation end products is decreased and inversely associated with acute phase response in chronic spontaneous urticaria. ( 26801062 )
2016
48
Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect? ( 27608479 )
2016
49
Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease. ( 27980778 )
2016
50
A Popular myth - low-histamine diet improves chronic spontaneous urticaria - fact or fiction? ( 27624921 )
2016

Variations for Urticaria

ClinVar genetic disease variations for Urticaria:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232

Expression for Urticaria

Search GEO for disease gene expression data for Urticaria.

Pathways for Urticaria

GO Terms for Urticaria

Biological processes related to Urticaria according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 cellular oxidant detoxification GO:0098869 9.61 LTC4S PTGS1 PTGS2
2 regulation of blood pressure GO:0008217 9.58 PTGS1 PTGS2 TAC1
3 response to lipopolysaccharide GO:0032496 9.56 PLCG2 PTGS2 SELE TAC1
4 positive regulation of receptor internalization GO:0002092 9.54 PLCG2 SELE
5 memory GO:0007613 9.54 HRH1 HRH2 PTGS2
6 prostaglandin metabolic process GO:0006693 9.52 PTGS1 PTGS2
7 leukotriene biosynthetic process GO:0019370 9.51 FCER1A LTC4S
8 lipoxygenase pathway GO:0019372 9.49 LTC4S PTGS2
9 prostaglandin biosynthetic process GO:0001516 9.48 PTGS1 PTGS2
10 cyclooxygenase pathway GO:0019371 9.46 PTGS1 PTGS2
11 positive regulation of vasoconstriction GO:0045907 9.33 HRH1 HRH2 PTGS2
12 cellular response to histamine GO:0071420 9.32 AOC1 HRH1
13 regulation of inflammatory response GO:0050727 9.26 CMA1 NLRP3 PTGS2 SELE
14 inflammatory response GO:0006954 9.23 ADGRE2 HRH1 MS4A2 NLRP3 PTGS1 PTGS2

Molecular functions related to Urticaria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 histamine receptor activity GO:0004969 9.16 HRH1 HRH2
2 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS1 PTGS2
3 IgE binding GO:0019863 8.8 FCER1A FCER2 MS4A2

Sources for Urticaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....